15
Participants
Start Date
August 25, 2022
Primary Completion Date
November 11, 2024
Study Completion Date
February 3, 2025
Dupilumab
Injection solution Subcutaneous
Columbia University Irving Medical Center Site Number : 8400003, New York
Boston Childrens Health Physicians Site Number : 8400017, Hawthorne
Pediatric Dermatology of Miami Site Number : 8400015, Coral Gables
Monroe Carell Jr. Childrens Hospital at Vanderbilt- Site Number : 8400005, Nashville
Childrens Hospital Medical Center of Akron- Site Number : 8400020, Akron
Washington University School of Medicine- Site Number : 8400004, St Louis
Vital Prospects Clinical Research Institute, P.C.- Site Number : 8400002, Tulsa
Treasure Valley Medical Research Site Number : 8400019, Boise
Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001, Cincinnati
Investigational Site Number : 1240009, Calgary
Investigational Site Number : 1240010, Edmonton
Investigational Site Number : 1240007, Hamilton
Investigational Site Number : 1240001, Montreal
Investigational Site Number : 3920001, Yokohama
Investigational Site Number : 3920002, Tsu
Lead Sponsor
Sanofi
INDUSTRY